results – Page 3 – pharmaceutical daily

March 14, 2019 Off

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Introduces Full Year 2019 Outlook

NEWTOWN, Pa.–(BUSINESS WIRE)–Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or
the “Company”), a neurotech company focused on neurological wellness,
today reported financial results for the fourth quarter and full y…

March 14, 2019 Off

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results

By BusinessWire

– Enrollment Completed in INVICTUS Pivotal Phase 3 Clinical Study in
Fourth-line and Fourth-line Plus GIST; Top-line Data Expected in
Mid-2019 –

– INTRIGUE Pivotal Phase 3 Clinical Study Initiated in Second-line
…

March 14, 2019 Off

BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

By BusinessWire

Completed Acquisition of Asterias Biotherapeutics, Inc.

Completed Distribution of AgeX Therapeutics Shares to BioTime
Shareholders

Entered Into Exclusive Collaboration with Orbit Biom…

January 15, 2018 Off

Sinclair posts strong final quarter 2017, sales up 20%

By Dino Mustafić

Sinclair pharma has reported revenue growth in excess of 80% over the last two years will, as expected, return the…

February 16, 2017 Off

Alexion doubles net income from last year, reduces investment in SBC-103

By Dino Mustafić

Alexion Pharmaceuticals’s revenues for 2016 increased 18% compared to the previous year, bringing $3.1 billion, and that’s with a negative impact of foreign currency of 3% or $74 million, bringing net income of $399 million, way up from $144 million last year.

February 14, 2017 Off

Moberg Pharma increases full year net profit

By Dino Mustafić

Moberg Pharma has posted net profit after tax of SEK 32.7 million (€3.45 million) which is up from SEK 25.5 million last year.

February 14, 2017 Off

Turbulent times for Teva, interim CEO focuses on enhancing value

By Dino Mustafić

Turbulent several months for Teva in which it saw many challenges and achievements saw the company loosing its CEO, several trials in the USA, one of which being for bribery, and patent related trials that Teva filed, and was filed against.

February 8, 2017 Off

GSK’s new products sales boost revenues, future demands

By Dino Mustafić

GlaxoSmithCline has posted net profit in the fourth quarter 2016 of £1,062 million and fully year £8,372, and turnover revenue growth of 6% with sales mounting to £27.9 billion, mainly driven by continued strong performance of new products.

February 2, 2017 Off

AstraZeneca’s sales drop, expects to launch several new drugs this year

By Dino Mustafić

AstraZeneca’s hopes to launch several cancer, respiratory and metabolic diseases drugs, as it expects to see the effects of its long-term growth. The drugmaker nears the end of its patent-expiry period as it expects to bring new medicines to the stores is.

February 1, 2017 Off

Pfizers full years earnings up 4%, Q1 2017 dividend rise 7%

By Dino Mustafić

Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.